Redeye: BrightBid: Setting the Organisation for Cost-Efficient Growth
Redeye somewhat cuts its forecasts and Base Case following a Q3 with soft ARR growth yet lower OPEX y/y. Given that BrightBid can accelerate growth – which management seems confident in following several new initiatives – it is heading towards profitability fast following the recent cost cuts. In such a scenario, the current 1.4x sales 2025e valuation looks appealing.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/